Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,575.04
(
-0.75%
)
US TECH 100
23,611.20
(
-0.78%
)
Dow Jones
45,807.30
(
-0.90%
)
Brent Oil
105.68
(
-0.85%
)
Bitcoin
69,661.54
(
-2.22%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 138150

Wednesday, 04/18/2012 9:40:53 AM

Wednesday, April 18, 2012 9:40:53 AM

Post# of 257259
Re: ABT-Galapagos JAK collaboration

Isn't ABT the partner one would want given their colossal success with Humira in the RA space? Really do think Galapagos has the right partner here. They just need to deliver on the data.

One fly in the ointment: ABT has its own in-house JAK inhibitor. Inasmuch as ABT has only taken an option (albeit an expensive one) on GLPG0634, ABT could yet end up backing its own JAK compound rather than the one from Galapagos.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now